Bertelsmann Investments Launches cormeo to Revolutionize Pharma Tech Solutions

Bertelsmann Investments Launches cormeo to Revolutionize Pharma Tech Solutions

(IN BRIEF) Bertelsmann Investments has launched cormeo, a new Pharma Tech holding company within its Bertelsmann Next growth unit, to consolidate the expertise of Docuvera, EXTEDO, and Rote Liste. cormeo is part of a broader strategy that includes Mobile Ad Tech and HR Tech, aimed at driving rapid growth in key sectors. The company is positioned to offer integrated solutions for managing and sharing regulated information across the drug lifecycle, leveraging innovative, AI-powered technologies. Senior executives from Bertelsmann Investments and cormeo underscored the strategic relevance of the Pharma Tech market and outlined plans for significant future investments. The new holding is set to establish industry benchmarks by enhancing data exchange among life sciences companies, health authorities, and healthcare professionals.

(PRESS RELEASE) GŪTTERSLOH, 4-Apr-2025 — /EuropaWire/ — Bertelsmann Investments (BI) today announced the launch of its new Pharma Tech holding company, cormeo, marking another step forward for the Bertelsmann Next growth unit. This new venture brings together the specialized expertise of Docuvera, EXTEDO, and Rote Liste under one unified umbrella. cormeo joins the ranks of Bertelsmann Next’s strategic focuses in Mobile Ad Tech (Applike), HR Tech (Embrace), and now Pharma Tech.

Carsten Coesfeld, CEO of Bertelsmann Investments, stated that the establishment of cormeo highlights the significant strategic importance of the Pharma Tech market. He noted that the Next growth program has been a driving force behind Bertelsmann’s expansion, with more than 130 percent organic growth in the 2024 financial year. Coesfeld expressed strong confidence in the potential of the Pharma Tech sector, which is why cormeo has been created to capitalize on emerging opportunities.

Deniz Pielsticker, CFO of Bertelsmann Investments and head of the Next unit, added that recent acquisitions of Rote Liste and EXTEDO, along with the investment in Docuvera, have greatly advanced the entrepreneurial development of their Pharma Tech division. He emphasized that further substantial investments are planned to drive additional growth in the coming years.

The new holding aims to offer a comprehensive solution for life sciences companies, health authorities, and healthcare professionals by managing and sharing regulated information throughout the drug lifecycle, from clinical trials to patient care. By merging the strengths of Docuvera, EXTEDO, and Rote Liste, cormeo intends to foster synergies among its brands and accelerate the creation of innovative, AI-powered solutions that enhance business processes and workflow efficiencies.

Peter Koop, CEO of cormeo, explained that the company will deliver a Smart Information Lifecycle for the industry, ensuring seamless and multidirectional exchange of regulated data. With its robust international footprint, cormeo is set to establish new benchmarks in the creation, management, and distribution of regulated information.

The management team at cormeo will include Peter Koop as CEO, Tobias Beer as COO Authoring & Distribution, Martin Schmid as COO Information Management, Schei Dattner as CSO/CPO, Pia Danne as VP Finance, and Ina Glaser as VP Marketing.

About Bertelsmann Investments
Bertelsmann Investments (BI) comprises Bertelsmann’s global venture capital activities as well as the Bertelsmann Next growth unit. The venture capital arm includes the Bertelsmann Asia Investments (BAI), Bertelsmann India Investments (BII), and Bertelsmann Digital Media Investments (BDMI) funds, as well as selected fund and direct holdings in markets including Europe, the United States, Brazil, Southeast Asia and Africa. The Bertelsmann Next unit advances the entrepreneurial development of new growth sectors and business areas, including Digital Health, HR Tech, and Mobile Ad Tech. To date, around €1.9 billion has been invested in around 500 innovative companies and funds through Bertelsmann Investments. Bertelsmann Investments currently holds over 370 active investments worldwide through its network of start-ups and funds.

About cormeo
cormeo unites the expertise of Docuvera, EXTEDO, and Rote Liste to provide a seamless end-to-end approach to creating, managing, and distributing regulated information in the life sciences sector. Together, we build the trusted bridge between industry, authorities, healthcare professionals, and patients, facilitating the innovative and compliant exchange of regulated information in life sciences to improve patient health.

At the core of information creation, Docuvera transforms content creation, review, approval, and translation by providing a solution for AI-powered structured content authoring. In the sphere of information management, EXTEDO provides regulatory information and quality management solutions to industry and authorities that support the entire lifecycle of medicinal products. For information distribution, Rote Liste plays a vital role in distributing medical information to healthcare professionals and patients, empowering them to make informed decisions with confidence.

cormeo is shaping the future of life science information management. With our strong commitment to digital transformation, compliance, and patient health, we empower the life sciences industry to enhance efficiency and innovation. For more information, please visit https://www.cormeo.com 

Media Contact:

Jan Hölkemann
Communications Bertelsmann Investments, Spokesperson / Communications Content Team
Phone: +49 (0) 52 41 80 89923
jan.hoelkemann@bertelsmann.de

SOURCE: Bertelsmann